Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The company traded as high as $35.19 and last traded at $32.11, with a volume of 947989 shares. The stock had previously closed at $27.49.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on MTSR. Bank of America initiated coverage on Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price target for the company. Guggenheim initiated coverage on Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $56.00 price objective on the stock. Evercore ISI initiated coverage on Metsera in a research note on Tuesday, February 25th. They set an "outperform" rating on the stock. Finally, Cantor Fitzgerald initiated coverage on Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating for the company.
Check Out Our Latest Research Report on MTSR
Metsera Stock Up 5.3%
The firm has a fifty day moving average price of $22.96.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Metsera
Institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG purchased a new stake in Metsera during the 1st quarter valued at about $374,000. Price T Rowe Associates Inc. MD bought a new position in Metsera during the 1st quarter valued at approximately $42,395,000. American Century Companies Inc. bought a new position in Metsera during the 1st quarter valued at approximately $7,791,000. Vanguard Group Inc. bought a new position in Metsera during the 1st quarter valued at approximately $39,932,000. Finally, Alpha Wave Global LP bought a new position in Metsera during the 1st quarter valued at approximately $64,894,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
